MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G(D2) immunotherapy

High-risk neuroblastoma (HR-NB) includes MYCN-amplified stage 2/3, but reports covering anti-G(D2) immunotherapy, which recently became standard for HR-NB, do not provide details on this subset. We now report on all 20 MYCN-amplified stage 2/3 patients who received induction chemotherapy at our cent...

Descripción completa

Detalles Bibliográficos
Autores principales: Kushner, Brian H., LaQuaglia, Michael P., Modak, Shakeel, Wolden, Suzanne L., Basu, Ellen M., Roberts, Stephen S., Kramer, Kim, Yataghene, Karima, Cheung, Irene Y., Cheung, Nai-Kong V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707022/
https://www.ncbi.nlm.nih.gov/pubmed/29221128
http://dx.doi.org/10.18632/oncotarget.20513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707022/
https://www.ncbi.nlm.nih.gov/pubmed/29221128
http://dx.doi.org/10.18632/oncotarget.20513

Ejemplares similares